From 7-8 February 2024, around 30 PANCAIM team members – researchers, AI developers, bioinformaticians, clinicians from 9 partner organisations in Europe – gathered in Prague for the project’s M36 meeting!

PANCAIM is dedicated to advancing multimodal AI integrating genomics, pathomics, and radiomics data for a more comprehensive understanding, diagnosis, and treatment of pancreatic cancer. Through the teamplay platform, we aim to bring our AI to the hospital for clinical validation and ensure brand new possibilities for clinicians to offer personalised treatment recommendations for PDAC patients.

We have been working hard for the last 3 years to achieve our objectives and develop tools to revolutionise pancreatic cancer care for hospitals and patients.

So what’s new?

  • There are some exciting updates on the AI models developed by partners and we are seeing some impressive results where AI could reach the same level or even outperform experienced clinicians!
  • As more and more data arrives in the repository, we are starting our validation efforts and testing developed models on previously unseen data via the Teamplay platform.
  • We identified current & future risks and brainstormed about mitigation actions to make sure we are prepared for these challenges.
  • During a dedicated session, we discussed the exploitation and sustainability plans to make sure that project result will continue to make an impact even after the end of the funded period.
  • With the upcoming project review meeting, we dedicated some time to rehearse presentations, align on priorities, and define the key messages to showcase the progress we’ve achieved through our collaborative efforts.

Thank you to all the partners for their active participation and contribution to the meeting, as well as AMIRES for their excellent organisation and hospitality!

We look forward to keeping you updated via this website, our social media (LinkedIn / Twitter) on future development and exciting results as PANCAIM continues to strive towards the clinical testing of selected best performing AI prototypes.